<i>Clostridium difficile</i> Colitis in Patients Undergoing Lower-extremity Arthroplasty: Rare Infection With Major Impact


Creative Commons License

Maltenfort M. G., Rasouli M. R., Morrison T. A., Parvizi J.

CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, cilt.471, sa.10, ss.3178-3185, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 471 Sayı: 10
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1007/s11999-013-2906-x
  • Dergi Adı: CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.3178-3185
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

The prevalence of Clostridium difficile colitis is reportedly increasing in surgical patients and can negatively impact their outcome. However, as yet there are no clear estimates of the C difficile infection colitis rate and its consequences among patients undergoing total joint arthroplasty (TJA). We asked: (1) What is the rate of C difficile colitis in TJA patients? (2) What are the risk factors of C difficile colitis in these patients? And (3) what is the effect of C difficile colitis on length of stay, in-hospital mortality, and estimated total charges? Using ICD-9-CM diagnosis and procedure codes, we queried the Nationwide Inpatient Sample database for patients undergoing TJA for the years 2002 to 2010. Demographic data, comorbidities, occurrence of C difficile colitis, length of hospital stay, mortality, and hospital charges were extracted. Logistic regression was performed to identify predictors of C difficile colitis and its impact on in-hospital mortality. The incidence of C difficile remained less than 0.6% during the study period. Revision TJAs (odds ratio = 6.9 and 4.4 for hip and knee, respectively) and number of comorbidities (odds ratio = 1.5) increased risk of C difficile colitis. C difficile increased length of hospital stay by a week, hospital charges by USD 40,000, and in-hospital mortality to 4.66% from 0.24%. Using lower and fewer doses of antibiotics in revision TJAs and among patients with many comorbidities may diminish risk of C difficile colitis and its consequent mortality. Level II, prognostic study. See Instructions for Authors for a complete description of levels of evidence.